Cuidados Paliativos en una paciente con Mesotelioma Peritoneal. Revisión de la literatura

[Palliative care in a patient with diagnosis of Peritoneal Mesothelioma. Case report and review of literature]
DOI: 10.37980/im.journal.rmdp.20221886
Publicado
2022-08-30

Descargas

Archivos adicionales

Autores/as

  • Maria Lim-Law Instituto Oncológico Nacional, Panamá, Panamá
  • Omar Castillo-Fernández Instituto Oncológico Nacional, Panamá, Panamá.
  • Lilian Montano Instituto Oncológico Nacional, Panamá, Panamá.
  • Rosibel Escobar Instituto Oncológico Nacional, Panamá, Panamá.

Palabras clave:

mesotelioma, cuidados paliativos

Keywords:

mesothelioma, palliative care

Resumen

Introducción: Los mesoteliomas peritoneales se origina de las células que recubren la serosa de las cavidades del cuerpo, el 15% se originan del peritoneo. Su incidencia de es 0.2 a 3 casos por millones de personal al año. Son tumores raros y su supervivencia global se limita hasta 12 meses. El objetivo de esta presentación de caso es describir una presentación atípica de esta entidad y realizar una revisión de la literatura. Materiales y métodos: Se realizó una descripción de un caso en la consulta externa de oncología diagnosticada con Mesotelioma papilar bien diferenciado de primario de peritoneo diagnosticada en el 2012 quien en el 2022 mantiene 10 años de supervivencia global y se realizó una revisión de la literatura en base al caso clínico.

Resultados:  Se define los tipos de mesotelioma peritoneal, sus características clínicas, el manejo del Mesotelioma Peritoneal según el Consenso de Chicago, los principios en cuidados de soporte como la ascitis peritoneal, el dolor, náuseas y vómitos, distrés psicosocial, así como la discusión del caso. Conclusión: El mesotelioma peritoneal es una enfermedad rara que puede ser rápidamente progresiva con una carga de enfermedad importante y pronóstico limitado. La instauración temprana de cuidados paliativos en pacientes con neoplasia incurable como el mesotelioma peritoneal permite el abordaje una mejor calidad de vida del paciente, así como de cumplir objetivos acordes a la situación clínica de cada paciente.


Abstract

Introduction: Peritoneal mesotheliomas originate from the cells lining the serosa of the body cavities, 15% originate from the peritoneum. Their incidence is 0.2 to 3 cases per million personnel per year. They are rare tumors and their overall survival is limited to 12 months. The aim of this case report is to describe an atypical presentation of this entity and to review the literature. Materials and methods: A description of a case was made in the oncology outpatient clinic diagnosed with well-differentiated papillary mesothelioma of primary peritoneum diagnosed in 2012 who in 2022 maintains 10 years of overall survival and a review of the literature was performed based on the clinical case. Results: We define the types of peritoneal mesothelioma, its clinical features, the management of peritoneal mesothelioma according to the Chicago Consensus, the principles in supportive care such as peritoneal ascites, pain, nausea and vomiting, psychosocial distress, as well as the discussion of the case. Conclusion: Peritoneal mesothelioma is a rare disease that can be rapidly progressive with a significant disease burden and limited prognosis. The early establishment of palliative care in patients with incurable neoplasm such as peritoneal mesothelioma allows the approach to a better quality of life of the patient, as well as to meet objectives according to the clinical situation of each patient.

Biografía del autor/a

Maria Lim-Law, Instituto Oncológico Nacional, Panamá, Panamá

Especialista en Medicina Interna y Oncología Médica en el Instituto Oncológico de Panmá 

Profesor Especial en la Universidad de Panama 

Citas

Bakitas, M. A., Tosteson, T. D., Li, Z., Lyons, K. D., Hull, J. G., Li, Z., Dionne-Odom, J. N., Frost, J., Dragnev, K. H., Hegel, M. T., Azuero, A., & Ahles, T. A. (2015). Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial. Journal of Clinical Oncology, 33(13), 1438-1445. DOI: https://doi.org/10.1200/jco.2014.58.6362

Bleicher, J., & Lambert, L. A. (2021). A Palliative Approach to Management of Peritoneal Carcinomatosis and Malignant Ascites. Surg Oncol Clin N Am, 30(3), 475-490. DOI: https://doi.org/10.1016/j.soc.2021.02.004

Chand, M. T., Edens, J., Lin, T., Anderson, I., & Berri, R. (2020). Benign multicystic peritoneal mesothelioma: literature review and update. Autopsy and Case Reports, 10(3). DOI: https://doi.org/10.4322/acr.2020.159

The Chicago Consensus on Peritoneal Surface Malignancies: Management of Peritoneal Mesothelioma. (2020a). Ann Surg Oncol, 27(6), 1774-1779. DOI: https://doi.org/10.1245/s10434-020-08324-w

The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma. (2020b). Cancer, 126(11), 2547-2552. DOI: https://doi.org/10.1002/cncr.32870

Churg, A., Allen, T., Borczuk, A. C., Cagle, P. T., Galateau-Sallé, F., Hwang, H., Murer, B., Murty, V. V., Ordonez, N., Tazelaar, H. D., & Wick, M. (2014). Well-differentiated Papillary Mesothelioma with Invasive Foci. American Journal of Surgical Pathology, 38(7), 990-998. DOI: https://doi.org/10.1097/pas.0000000000000200

Dans Maria, K. J. (2021). Palliative Care. In N. Guidelines (Ed.), (pp. 1-103). www.NCCN.org.

Dionne-Odom, J. N., Azuero, A., Lyons, K. D., Hull, J. G., Tosteson, T., Li, Z., Li, Z., Frost, J., Dragnev, K. H., Akyar, I., Hegel, M. T., & Bakitas, M. A. (2015). Benefits of Early Versus Delayed Palliative Care to Informal Family Caregivers of Patients with Advanced Cancer: Outcomes From the ENABLE III Randomized Controlled Trial. Journal of Clinical Oncology, 33(13), 1446-1452. DOI: https://doi.org/10.1200/jco.2014.58.7824

Ettinger, D. (2021). Malignant Peritoneal Mesothelioma. In NCCN guidelines (Vol. V1.2022, pp. 1-24).

Ferrell, B. R., Temel, J. S., Temin, S., Alesi, E. R., Balboni, T. A., Basch, E. M., Firn, J. I., Paice, J. A., Peppercorn, J. M., Phillips, T., Stovall, E. L., Zimmermann, C., & Smith, T. J. (2017). Integration of Palliative Care into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 35(1), 96-112. DOI: https://doi.org/10.1200/jco.2016.70.1474

Fleming, N. D., Alvarez-Secord, A., Von Gruenigen, V., Miller, M. J., & Abernethy, A. P. (2009). Indwelling Catheters for the Management of Refractory Malignant Ascites: A Systematic Literature Overview and Retrospective Chart Review. Journal of Pain and Symptom Management, 38(3), 341-349. DOI: https://doi.org/10.1016/j.jpainsymman.2008.09.008

Gushchin, V., Demmy, T. L., & Kane, J. M., 3rd. (2007). Surgical management of metastatic peritoneal or pleural disease. Semin Oncol, 34(3), 215-225. DOI: https://doi.org/10.1053/j.seminoncol.2007.03.009

Harrison, M., Gardiner, C., Taylor, B., Ejegi-Memeh, S., & Darlison, L. (2021). Understanding the palliative care needs and experiences of people with mesothelioma and their family carers: An integrative systematic review. Palliat Med, 35(6), 1039-1051. DOI: https://doi.org/10.1177/02692163211007379

Lambert, L. A., & Hendrix, R. J. (2018). Palliative Management of Advanced Peritoneal Carcinomatosis. Surg Oncol Clin N Am, 27(3), 585-602. DOI: https://doi.org/10.1016/j.soc.2018.02.008

Lee, Y. K., Jun, H. J., Nahm, J. H., Lim, T. S., Park, J. S., Ahn, J. B., Rha, S. Y., Chung, H. C., Oh, H. E., Song, J. S., Yang, W. I., & Kim, H. S. (2013). Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum. Jón J Clin Oncol, 43(10), 996-1003. DOI: https://doi.org/10.1093/jjco/hyt117

McDonald, J., Swami, N., Hannon, B., Lo, C., Pope, A., Oza, A., Leighl, N., Krzyzanowska, M. K., Rodin, G., Le, L. W., & Zimmermann, C. (2017). Impact of early palliative care on caregivers of patients with advanced cancer: cluster randomised trial. Ann Oncol, 28(1), 163-168. DOI: https://doi.org/10.1093/annonc/mdw438

Noiret, B., Renaud, F., Piessen, G., & Eveno, C. (2019). Multicystic peritoneal mesothelioma: a systematic review of the literature. Pleura and Peritoneum, 4(3). DOI: https://doi.org/10.1515/pp-2019-0024

Odgerel, C.-O., Takahashi, K., Sorahan, T., Driscoll, T., Fitzmaurice, C., Yoko-O, M., Sawanyawisuth, K., Furuya, S., Tanaka, F., Horie, S., Zandwijk, N. V., & Takala, J. (2017). Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occupational and Environmental Medicine, 74(12), 851-858. DOI: https://doi.org/10.1136/oemed-2017-104298

Patriti, A., Cavazzoni, E., Graziosi, L., Pisciaroli, A., Luzi, D., Gullà, N., & Donini, A. (2008). Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy. Surg Laparosc Endosc Percutan Tech, 18(4), 426-428. DOI: https://doi.org/10.1097/SLE.0b013e318173a61e

Riba, M. B., Donovan, K. A., Andersen, B., Braun, I., Breitbart, W. S., Brewer, B. W., Buchmann, L. O., Clark, M. M., Collins, M., Corbett, C., Fleishman, S., Garcia, S., Greenberg, D. B., Handzo, R. G. F., Hoofring, L., Huang, C.-H., Lally, R., Martin, S., McGuffey, L., . . . Darlow, S. D. (2019). Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17(10), 1229-1249. DOI: https://doi.org/10.6004/jnccn.2019.0048

Salo, S. A. S., Ilonen, I., Laaksonen, S., Myllarniemi, M., Salo, J. A., & Rantanen, T. (2017). Epidemiology of malignant peritoneal mesothelioma: A population-based study. Cancer Epidemiol, 51, 81-86. DOI: https://doi.org/10.1016/j.canep.2017.10.008

Salpeter, S. R., Malter, D. S., Luo, E. J., Lin, A. Y., & Stuart, B. (2012). Systematic review of cancer presentations with a median survival of six months or less. J Palliat Med, 15(2), 175-185. DOI: https://doi.org/10.1089/jpm.2011.0192

Severs, M., Rabban, J. T., Garg, K., Van Ziffle, J., Onodera, C., Grenert, J. P., Yeh, I., Bastian, B. C., Zaloudek, C., & Solomon, D. A. (2019). Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42. Mod Pathol, 32(1), 88-99. DOI: https://doi.org/10.1038/s41379-018-0127-2

Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., Billings, J. A., & Lynch, T. J. (2010). Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer. New England Journal of Medicine, 363(8), 733-742. DOI: https://doi.org/10.1056/nejmoa1000678

Tinkler, M., Royston, R., & Kendall, C. (2017). Palliative care for patients with mesothelioma. Br J Hosp Med (Lond), 78(4), 219-225. DOI: https://doi.org/10.12968/hmed.2017.78.4.219

Travis, W. D. (2004). Who Classification of Tumors of the Lung, Pleura, Thymus and Heart (W. D. Travis & E. Brambilla, Eds.). IARC Press.

Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., Geisinger, K., Hirsch, F. R., Ishikawa, Y., Kerr, K. M., Noguchi, M., Pelosi, G., Powell, C. A., Tsao, M. S., & Wistuba, I. (2015). The 2015 World Health Organization Classification of Lung Tumors. Journal of Thoracic Oncology, 10(9), 1243-1260. DOI: https://doi.org/10.1097/jto.0000000000000630

Zhang, C. H., Yu, J. W., & Luo, M. (2017). Multicystic peritoneal mesothelioma: A short review. Curr Probl Cancer, 41(5), 340-348. DOI: https://doi.org/10.1016/j.currproblcancer.2017.03.002